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Life-threatening toxic epidermal
necrolysis during voriconazole
therapy for invasive aspergillosis
after chemotherapy
In patients with invasive aspergillosis, initial therapy with
voriconazole led to better responses and improved survival and
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resulted in fewer severe side effects than the standard approach
of initial therapy with amphotericin B [1]. We report a case
of life-threatening toxic epidermal necrolysis related with the
use of voriconazole in a patient with pulmonary invasive
aspergillosis.
A 39-year-old man affected by breast cancer with brain and
lung metastases developed a pulmonary aspergillosis during
chemotherapy (Cisplatin 60 mg/m2 day 1, 21, Epirubicin
50 mg/m2 day 1, 21 and continuous infusion 5-fluorouracil
200 mg/m2 day 1–21). We started voriconazole treatment
with two doses of 6 mg per kilogram of body weight on day 1,
then 4 mg per kilogram twice daily for seven days followed by
200 mg orally twice daily. Concomitant drugs were
phenythoine 100 mg twice daily and subcutaneously
dexamethasone 4 mg once daily (the two drugs were both
assumed since 14 weeks). Chemotherapy was discontinued.
Five days after the oral voriconazole was started, the patient
noticed a rash, and all drugs were discontinued. Within three
days, he had fever and diffuse erythema of the trunk,
extremities, and face, with blistering skin lesions and positive
Nikolsky’s sign on erythematous areas, characteristic of toxic
epidermal necrolysis. Rash and detachment toxic epidermal
necrolysis involved 85% of the body surface (Figure 1). The
conjunctivae were injected, and multiple bullae and ulcers were
present on the lips and oropharyngeal mucosa. Skin biopsy
histology showed necrosis of cells from the basal layer and
stratum spinosum resulting in detachment of the epidermis
from the dermis as toxic epidermal necrolysis. Patient had
impaired alimentation, photophobia, and haematuria. Blood
cultures yielded gram-negative rods later identified as
Pseudomonas aeruginosa, sensitive to imipenem. Due to clinical
conditions the patient was hospitalized in the intensive care
unit. We treated the patient with human intravenous
immunoglobulins at dose of 0.5 g/kg of body weight per day
for four consecutive days [2], adding imipenem 4 g per day in
four administrations for 10 days. The patient recovered after
2 weeks of intensive therapy.
To our knowledge, this is the first report of voriconazole
related toxic epidermal necrolysis. Voriconazole is a new
broad-spectrum triazole that has been demonstrated as
superior over amphotericin B as initial therapy for invasive
aspergillosis, in terms of response rate, survival rate, and safety.
Caution should be exercised when combining voriconazole
with other drugs known to cause skin reaction, such as
phenythoine.
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Figure 1. Rash and detachment toxic epidermal necrolysis involving
85% of the body surface following therapy with voriconazole.
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